International markets can be difficult to access for Australian MTP sector companies, with a number of challenges to entry. As part of the MTPConnect Project Fund Program, an Asialink Business project commenced in 2019 to identify opportunities for Australian companies to access global markets.
The National Biologics Training Program - born out of The University of Queensland - has set up an international collaboration with Thailand's Centre of Excellence for Life Sciences (TCELS) to provide its biopharmaceutical researchers with professional development training to strengthen capabilities in Biologics R&D, advanced biomanufacturing and global regulation.
Start-up accelerator The MedTech Actuator has formed a collaboration with venture capital firm Artesian Ventures to create new growth opportunities for medtech start-ups.
A new device under development at the Bionics Institute in Melbourne is set to improve the quality of life for deaf infants and children.
In its inaugural year in 2018, the BridgeTech Program hosted 80 applicants who were eager to learn more about commercialising their medical technology and medical devices ideas and products.
Canberra-based healthtech start-up Health Horizon identified a gap between research and translation in Australia - how can someone search for an exciting development in Australian health innovation?
The University of Technology, Sydney (UTS) is the only university in the Asia-Pacific region that offers the Good Manufacturing Practice (GMP) degree.
2018 was a busy year for South Australia-based Carina Biotech, with many exciting developments. The company is aiming to conduct the first-in-human clinical trial of its CAR-T product candidate in Australia in 2020 and were awarded a Cooperative Research Centres Project (CRC-P) Round 6 grant.
Indee Labs mission is to make gene-modified cell therapies (GMCTs), a new generation of medicines with the potential to cure many diseases which are currently incurable, easily accessible to the general public.
Around one in 5,000 babies are born worldwide with a malformation of the outer ear, a condition known as microtia. It can cause severe emotional and psychosocial distress for children, if there's no intervention.
Accelerating Australia is well into its next phase of the project, which gives entrepreneurs, business professionals and start-ups the skills they need to translate and commercialise their biomedical ideas.
Vaccines are one of the fastest growing sectors in the pharmaceutical and biotechnology industry. Vaccine technology developer Vaxine, in a project with partners Mylexa and the Australian Respiratory and Sleep Medicine Institute (ARASMI), is bringing together a community of researchers, developers and industries to drive growth of Australian vaccine development.
The AusBiotech Sector Snapshot (October 2017) revealed that there are currently over 130 ASX-listed life sciences companies with a market capitalisation of over $50 billion. It's indicative of a burgeoning sector that is one of the key areas of economic growth in Australia.